# A Study of GC3107(BCG Vaccine) in Healthy Infants

> **NCT03947138** · PHASE3 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 750 (actual)

## Conditions studied

- BCG Vaccination Reaction
- Tuberculosis

## Interventions

- **BIOLOGICAL:** GC3107
- **BIOLOGICAL:** Intradermal BCG SSI inj.

## Key facts

- **NCT ID:** NCT03947138
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-06
- **Primary completion:** 2022-06-20
- **Final completion:** 2022-09-06
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2022-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947138, "A Study of GC3107(BCG Vaccine) in Healthy Infants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03947138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*